REGN7257

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals

Conditions

Severe Aplastic Anemia (SAA)Severe aplastic anemia (SAA)

Phase 1

REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy

TerminatedNCT04409080

Regeneron PharmaceuticalsSevere Aplastic Anemia (SAA)

Start: 2021-01-13End: 2024-10-17Updated: 2026-06-22

A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients with Severe Aplastic Anemia that is Refractory to or Relapsed on Immunosuppressive Therapy

CompletedCTIS2023-508601-24-00

Regeneron Pharmaceuticals Inc.Severe aplastic anemia (SAA)

Start: 2021-09-13End: 2025-06-16Target: 14Updated: 2024-10-24